OppenheimerFunds Inc. grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 2.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 177,832 shares of the company’s stock after acquiring an additional 4,186 shares during the quarter. OppenheimerFunds Inc.’s holdings in Zoetis were worth $12,811,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. First Trust Advisors LP lifted its stake in Zoetis by 4,888.0% during the third quarter. First Trust Advisors LP now owns 200,468 shares of the company’s stock worth $12,782,000 after purchasing an additional 196,449 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Zoetis by 16.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 36,268 shares of the company’s stock worth $2,313,000 after purchasing an additional 5,227 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Zoetis by 2.5% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 81,440 shares of the company’s stock worth $5,193,000 after purchasing an additional 1,970 shares during the last quarter. Gabelli Funds LLC lifted its stake in Zoetis by 13.6% during the third quarter. Gabelli Funds LLC now owns 780,454 shares of the company’s stock worth $49,762,000 after purchasing an additional 93,395 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in Zoetis by 8.6% in the third quarter. Daiwa Securities Group Inc. now owns 16,131 shares of the company’s stock worth $1,029,000 after buying an additional 1,281 shares during the period. 92.45% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Heidi C. Chen sold 37,453 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Roman Trawicki sold 8,568 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $83.10, for a total value of $712,000.80. Following the completion of the transaction, the insider now directly owns 11,457 shares of the company’s stock, valued at $952,076.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,569 shares of company stock valued at $8,594,429. 0.31% of the stock is currently owned by corporate insiders.
Shares of Zoetis Inc (NYSE ZTS) traded down $0.22 during mid-day trading on Wednesday, reaching $84.37. The company had a trading volume of 1,167,722 shares, compared to its average volume of 2,868,004. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. The firm has a market cap of $40,960.27, a price-to-earnings ratio of 48.30, a price-to-earnings-growth ratio of 1.89 and a beta of 0.97. Zoetis Inc has a twelve month low of $52.25 and a twelve month high of $85.54.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 earnings per share. research analysts anticipate that Zoetis Inc will post 3.04 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be given a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. Zoetis’s payout ratio is currently 28.57%.
A number of research analysts recently issued reports on the company. Citigroup raised Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Thursday, January 4th. Jefferies Group set a $97.00 price target on Zoetis and gave the company a “buy” rating in a research report on Monday, February 26th. BMO Capital Markets reiterated a “hold” rating on shares of Zoetis in a research report on Monday, January 8th. Piper Jaffray Companies restated a “buy” rating and set a $86.00 price objective on shares of Zoetis in a research report on Thursday, January 18th. Finally, UBS Group restated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $80.28.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/03/14/oppenheimerfunds-inc-acquires-4186-shares-of-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.